The gene editing market is forecast to observe tremendous growth owing to the increasing government-sponsored regulatory support for more effective and better treatments for genetic disorders. This government support is a response to the rapidly growing prevalence of different genetic diseases throughout the globe.

Consequently, regulatory agencies are increasingly partnering with other organizations to grant a helping hand to the development of affordable gene therapies that treat diseases like HIV and sickle cell anemia. Citing an instance, in 2019, the National Institutes of Health as well as the Bill & Melinda Gates Foundation teamed up to invest $100 million each to help with the development of more affordable and effective gene therapies and make them readily available worldwide. 

Request for a sample copy of this report @ https://www.decresearch.com/request-sample/detail/810  

As per a research report by Global Market Insights Inc., the gene editing market is likely to exceed a valuation of $10 billion by the end of 2026.

With respect to application, in 2019, the plant genetic engineering segment held approximately 19% of the overall industry share. A growing preference for crops that are genetically modified is a major factor proliferating the segment share. Such crops have numerous advantages in terms of increasing agricultural productivity and decreasing the requirement for environmentally harmful pesticides. Additionally, the segment would also observe significant growth attributing to the ready availability of various technologically advanced procedures of gene editing that are used for altering plant genome.

Based on end-use, the market is bifurcated into pharma and biotech companies, research institutes, and CROs (Contract Research Organizations). Of these, CROs accounted for an industry valuation of over $900 million in 2019. Numerous CROs are constantly working to innovate advanced gene editing tools like CRISPR/Cas9 and TALENS. ACF Bio services, PSI, and Med pace are among the major CROs working to develop such tools. In addition, CROs have subject matter experts that have deep knowledge of the regulations and developments associated with enhanced gene therapy products, which should positively influence the segment outlook in the coming years.

Geographically, rising presence of genetic research organizations that are focusing towards developing advanced and innovative gene editing tools, especially across developing economies, would positively impel the Asia Pacific gene editing market. In fact, increasing research activities related to gene editing across emerging economies like India, and Japan would prove to be highly beneficial for regional industry growth. The Asia Pacific gene editing industry is projected to register a CAGR of about 15% throughout the analysis period.

Request for customization @ https://www.decresearch.com/roc/810

Speaking of industry players, of late, the market is increasingly witnessing strategic collaborations as more and more enterprises focus on staking a bigger claim of the overall industry landscape. Takin May 2020 for instance, Caribou Science, a renowned CRISPR genome editing firm, signed a clinical and commercial license deal with MaxCyte, a US-based biotechnology firm. The agreement gave Caribou exclusive rights to MaxCyte’s ExPERT platform and Flow Electroporation technology. This will help Caribou the ability to advance its CRISPR-based gene-edited allogeneic T cell treatment programs.

The competitive landscape of the gene editing market is inclusive of players such as Beam Therapeutics, Caribou Biosciences, Origene Technologies, EMD Millipore (Merck KGAa), Precision Biosciences, Inc., Thermo Fisher Scientific, Sangamo Therapeutics, Takara Bio, Agilent Technologies, Horizon Discovery, and Integrated DNA Technologies among others.

Partial Chapter of the Table of Content

Chapter 2.    Executive Summary

2.1. Gene editing industry 360⁰ synopsis, 2015 - 2026

2.1.1.    Business trends

2.1.2.    Application trends

2.1.3.    Technology trends

2.1.4.    End-user trends

2.1.5.    Regional trends

Chapter 3.    Gene Editing Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2015 - 2026

3.3. Industry impact forces

3.3.1.    Growth drivers

3.3.1.1.    Increased funding for genetic research in North America

3.3.1.2.    Rising R&D expenditure and growth of biotechnology in Europe

3.3.1.3.    Increasing demand for synthetic genes in Asia Pacific and North America

3.3.1.4.    Technology advancements in gene editing in North America

3.3.2.    Industry pitfalls and challenges

3.3.2.1.    Stringent government regulations

3.3.2.2.    Lack of public awareness in underdeveloped economies

3.4. Growth potential analysis

3.4.1.    By application

3.4.2.    By technology

3.4.3.    By end-user

3.5. COVID-19 impact analysis

3.6. Competitive landscape, 2019

3.6.1.    Strategy dashboard, 2019

3.7. Porter’s analysis

3.8. PESTEL analysis

Browse complete Table of Contents (ToC) of this research report @ https://www.decresearch.com/toc/detail/gene-editing-market